🇪🇺 PF-06863135 monotherapy IV or SC in European Union

PF-06863135 monotherapy IV or SC (pf-06863135-monotherapy-iv-or-sc) regulatory status in European Union.

Marketing authorisation

EMA

  • Status: approved

PF-06863135 monotherapy IV or SC in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is PF-06863135 monotherapy IV or SC approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for PF-06863135 monotherapy IV or SC in European Union?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.